Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients

Daclizumab was approved by the FDA and the EMA in 2016 for the treatment of relapsing forms of multiple sclerosis (MS). Cases of severe inflammatory brain disease with fatal outcome led to the withdrawal of approval in Europe and the US on March 2, 2018. Approximately 8,000 patients worldwide receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rommer, Paulus S., Berger, Klaus, Ellenberger, David, Fneish, Firas, Simbrich, Alexandra, Stahmann, Alexander, Zettl, Uwe K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506133/
https://www.ncbi.nlm.nih.gov/pubmed/33013658
http://dx.doi.org/10.3389/fneur.2020.00996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506133/
https://www.ncbi.nlm.nih.gov/pubmed/33013658
http://dx.doi.org/10.3389/fneur.2020.00996

Ejemplares similares